ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

D352

A development code.

Its studies are mostly in Dyslipidemias, led by Chong Kun Dang Pharmaceutical.

Furthest: phase 1, since Dec 26, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chong Kun Dang Pharmaceutical10 open or runningphase 1since Dec 26, 2024Dec 26, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 26, 2024First study: phase 1 study in DyslipidemiasFirst studyNCT06758661 · 40 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06758661Dyslipidemias · Korea, Republic of1CompletedJan 24, 202540

How it is read

Names in the registry

  • “D352”, 1 entry

Codes read as this program: D352.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.